See more : Land & Homes Group Limited (LHM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Apyx Medical Corporation (APYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apyx Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Mijem Newcomm Tech Inc. (MJEM.CN) Income Statement Analysis – Financial Results
- AT&T Inc. 5.625% Global Notes d (TBC) Income Statement Analysis – Financial Results
- BioMarin Pharmaceutical Inc. (BMRN) Income Statement Analysis – Financial Results
- Watami Co., Ltd. (7522.T) Income Statement Analysis – Financial Results
- Blackout Media Corp. (BKMP) Income Statement Analysis – Financial Results
Apyx Medical Corporation (APYX)
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.35M | 44.51M | 48.52M | 27.71M | 28.15M | 16.69M | 38.88M | 36.63M | 29.52M | 27.68M | 23.66M | 27.67M | 25.41M | 24.23M | 26.95M | 28.10M | 28.78M | 26.68M | 20.21M | 20.50M | 16.55M | 12.45M | 11.48M | 9.94M | 9.60M | 8.44M | 7.37M | 7.49M | 5.52M |
| Cost of Revenue | 18.59M | 15.38M | 14.92M | 10.21M | 9.03M | 5.89M | 19.12M | 18.71M | 16.96M | 18.69M | 14.46M | 16.34M | 14.68M | 14.24M | 15.10M | 16.25M | 17.46M | 16.08M | 12.65M | 12.51M | 9.43M | 7.19M | 5.72M | 4.60M | 4.59M | 5.27M | 4.14M | 4.13M | 3.22M |
| Gross Profit | 33.76M | 29.13M | 33.60M | 17.50M | 19.13M | 10.79M | 19.76M | 17.92M | 12.56M | 8.99M | 9.20M | 11.33M | 10.73M | 9.99M | 11.85M | 11.85M | 11.32M | 10.60M | 7.56M | 7.98M | 7.12M | 5.26M | 5.76M | 5.34M | 5.01M | 3.17M | 3.23M | 3.35M | 2.31M |
| Gross Profit Ratio | 64.49% | 65.45% | 69.26% | 63.17% | 67.94% | 64.68% | 50.82% | 48.91% | 42.54% | 32.48% | 38.88% | 40.96% | 42.23% | 41.22% | 43.98% | 42.17% | 39.32% | 39.74% | 37.41% | 38.94% | 43.00% | 42.23% | 50.15% | 53.74% | 52.19% | 37.53% | 43.85% | 44.77% | 41.76% |
| Research & Development | 4.84M | 4.54M | 4.32M | 3.92M | 3.81M | 2.47M | 2.46M | 2.62M | 2.16M | 1.42M | 1.26M | 1.33M | 1.20M | 1.85M | 2.08M | 2.06M | 1.64M | 1.19M | 985.81K | 907.39K | 717.35K | 693.71K | 463.13K | 513.02K | 379.83K | 183.17K | 96.74K | 105.70K | 121.90K |
| General & Administrative | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.30M | 1.30M | 800.00K | 1.50M | 800.00K | 11.37M | 8.57M | 8.42M | 6.69M | 4.89M | 4.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 8.50M | 7.57M | 6.79M | 6.01M | 5.76M | 5.60M | 4.91M | 4.71M | 3.90M | 6.46M | 1.75M | 0.00 | 1.34M | 1.18M |
| Other Expenses | 0.00 | 509.00K | -373.00K | 479.00K | -382.00K | -203.00K | -11.37M | -8.57M | -8.42M | -6.69M | -4.89M | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.19K | 39.29K | 81.91K | 124.45K | 0.00 | 396.81K | 321.17K | 2.15M | 2.80M | 1.43M | 1.22M |
| Operating Expenses | 51.02M | 52.69M | 48.05M | 37.59M | 40.04M | 23.65M | 23.50M | 21.71M | 19.54M | 14.84M | 11.22M | 10.29M | 11.50M | 11.45M | 11.14M | 10.56M | 9.21M | 7.98M | 7.16M | 6.70M | 6.40M | 5.73M | 5.18M | 4.81M | 7.16M | 4.09M | 2.89M | 2.87M | 2.53M |
| Cost & Expenses | 69.61M | 68.07M | 62.97M | 47.79M | 49.07M | 29.55M | 42.62M | 40.42M | 36.51M | 33.53M | 25.69M | 26.63M | 26.18M | 25.70M | 26.24M | 26.81M | 26.67M | 24.05M | 19.81M | 19.22M | 15.84M | 12.92M | 10.90M | 9.41M | 11.75M | 9.36M | 7.03M | 7.01M | 5.74M |
| Interest Income | 921.00K | 157.00K | 11.00K | 241.00K | 1.39M | 616.00K | 0.00 | 0.00 | 1.00K | 0.00 | 7.00K | 0.00 | 12.00K | 0.00 | 24.36K | 48.76K | 142.72K | 103.09K | 46.96K | 3.26K | 2.98K | 5.21K | 10.11K | 28.75K | 0.00 | 4.16K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.48M | 15.00K | 10.00K | 46.00K | 8.00K | 104.00K | 136.00K | 158.00K | 158.00K | 151.00K | 237.00K | 232.00K | 249.00K | 223.00K | 76.37K | 58.46K | 2.47K | 16.16K | 22.70K | 15.09K | 34.06K | 48.45K | 70.69K | 66.80K | 0.00 | 103.84K | 0.00 | 75.80K | 68.70K |
| Depreciation & Amortization | 692.00K | 890.00K | 903.00K | 887.00K | 754.00K | 669.00K | 696.00K | 734.00K | 812.00K | 876.00K | 827.00K | 857.00K | 925.00K | 1.01M | 1.05M | 973.07K | 770.83K | 529.26K | 545.88K | 395.12K | 314.68K | 274.88K | 524.24K | 396.81K | 321.17K | 787.09K | 311.14K | 260.60K | 171.00K |
| EBITDA | -18.11M | -22.01M | -13.91M | -18.48M | -19.07M | -13.92M | -13.01M | -3.79M | -4.37M | -12.25M | -3.68M | 1.93M | 1.19M | -1.23M | 1.79M | 3.81M | 2.88M | 3.15M | 949.84K | 1.67M | 978.14K | -199.02K | 1.16M | 926.71K | 947.21K | -133.07K | 650.72K | 741.00K | -48.50K |
| EBITDA Ratio | -34.60% | -51.44% | -30.53% | -69.87% | -70.69% | -78.28% | -9.62% | -10.35% | -23.67% | -21.13% | -10.17% | 6.88% | 3.62% | 1.29% | 6.64% | 2.74% | 10.00% | 11.82% | 4.70% | 8.17% | 6.70% | -0.62% | 9.21% | 9.24% | -19.07% | -1.83% | 8.36% | 9.75% | -1.92% |
| Operating Income | -17.26M | -23.56M | -14.45M | -20.08M | -20.91M | -13.60M | -5.27M | -3.79M | -6.99M | -5.85M | -3.67M | 1.05M | -18.00K | -2.75M | 714.85K | 1.29M | 2.11M | 2.62M | 403.97K | 1.28M | 712.40K | -473.90K | 583.58K | 529.90K | -2.15M | -920.16K | 339.58K | 480.40K | -219.50K |
| Operating Income Ratio | -32.97% | -52.94% | -29.78% | -72.47% | -74.28% | -81.51% | -13.54% | -10.35% | -23.67% | -21.13% | -15.49% | 3.78% | -0.07% | -11.36% | 2.65% | 4.60% | 7.32% | 9.84% | 2.00% | 6.24% | 4.30% | -3.81% | 5.08% | 5.33% | -22.38% | -10.90% | 4.61% | 6.42% | -3.98% |
| Total Other Income/Expenses | -4.02M | 651.00K | -372.00K | 674.00K | 1.03M | -1.09M | -8.57M | -94.00K | 1.64M | -7.44M | -2.29M | -212.00K | 50.00K | 290.00K | -52.01K | 1.49M | 140.25K | 86.93K | 24.26K | -11.83K | -31.08K | -40.87K | -431.47K | 8.79K | 3.25K | -77.88K | -240.39K | -64.80K | 65.40K |
| Income Before Tax | -21.28M | -22.91M | -14.82M | -19.41M | -19.91M | -13.27M | -5.22M | -3.89M | -5.35M | -13.29M | -5.95M | 834.00K | 32.00K | -2.46M | 662.84K | 2.78M | 2.25M | 2.71M | 428.22K | 1.27M | 681.32K | -514.77K | 200.59K | 538.69K | -2.14M | -998.05K | 99.19K | 415.60K | -154.10K |
| Income Before Tax Ratio | -40.65% | -51.47% | -30.55% | -70.04% | -70.72% | -79.53% | -13.42% | -10.61% | -18.11% | -47.99% | -25.16% | 3.01% | 0.13% | -10.16% | 2.46% | 9.88% | 7.81% | 10.16% | 2.12% | 6.18% | 4.12% | -4.14% | 1.75% | 5.42% | -22.35% | -11.82% | 1.35% | 5.55% | -2.79% |
| Income Tax Expense | -2.43M | 367.00K | 380.00K | -7.50M | -260.00K | -3.78M | -156.00K | 64.00K | 25.00K | 4.00M | -1.61M | 217.00K | -77.00K | -927.00K | 67.32K | 945.42K | -148.84K | 47.57K | 32.02K | -272.72K | 31.08K | 40.87K | -211.19K | 29.27K | 35.81K | 77.88K | 240.39K | 8.30K | -65.40K |
| Net Income | -18.71M | -23.28M | -15.20M | -11.91M | -19.65M | 64.01M | -5.06M | -3.95M | -5.37M | -17.28M | -4.34M | 617.00K | 109.00K | -1.54M | 595.52K | 1.83M | 2.40M | 2.68M | 406.21K | 1.51M | 681.32K | -514.77K | 784.29K | 500.63K | -2.18M | -998.05K | 99.19K | 407.30K | -154.10K |
| Net Income Ratio | -35.75% | -52.30% | -31.33% | -42.96% | -69.79% | 383.61% | -13.02% | -10.78% | -18.19% | -62.43% | -18.34% | 2.23% | 0.43% | -6.34% | 2.21% | 6.52% | 8.34% | 10.06% | 2.01% | 7.38% | 4.12% | -4.14% | 6.83% | 5.04% | -22.75% | -11.82% | 1.35% | 5.44% | -2.79% |
| EPS | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.93 | -0.16 | -0.14 | -0.22 | -0.98 | -0.25 | 0.04 | 0.01 | -0.09 | 0.04 | 0.11 | 0.15 | 0.19 | 0.03 | 0.11 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| EPS Diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.86 | -0.16 | -0.14 | -0.19 | -0.97 | -0.25 | 0.03 | 0.01 | -0.09 | 0.03 | 0.11 | 0.13 | 0.16 | 0.03 | 0.09 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| Weighted Avg Shares Out | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 33.19M | 31.42M | 27.43M | 24.33M | 17.68M | 17.49M | 17.63M | 17.60M | 17.37M | 16.90M | 16.07M | 15.32M | 14.54M | 13.92M | 13.75M | 13.63M | 13.20M | 13.45M | 13.90M | 13.88M | 13.88M | 8.19M | 7.66M | 4.35M |
| Weighted Avg Shares Out (Dil) | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 34.37M | 31.43M | 27.45M | 27.75M | 17.76M | 17.67M | 17.79M | 17.67M | 17.37M | 17.84M | 17.09M | 17.68M | 16.91M | 15.75M | 16.80M | 13.63M | 14.41M | 14.76M | 16.07M | 13.88M | 13.88M | 8.44M | 7.66M | 4.35M |
Apyx Medical Corporation (APYX) Q3 2022 Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Charles Goodwin - President and Chief Executive Officer Tara Semb - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital...
Apyx Medical (APYX) Reports Q3 Loss, Misses Revenue Estimates
Apyx (APYX) delivered earnings and revenue surprises of -41.67% and 24.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2022, and updated financial expectations for...
Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2022, and updated financial expectations for...
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2022 Financial Results on November 10, 2022
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2022 will be released before...
'BOTCHED' TV STAR DR. PAUL NASSIF AMONG TOP U.S. PLASTIC SURGEONS USING RENUVION® HELIUM PLASMA TECHNOLOGY IN COSMETIC PROCEDURES
Doctors Attest to Advanced Energy Technology Device's Transformative Solutions to Achieve Desired Results in Patients CLEARWATER, Fla. , Sept. 13, 2022 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed...
Apyx Medical Corporation to Participate in the Lake Street Best Ideas Growth Conference
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Lake Street Best Ideas Growth Conference, which is being...
Apyx Medical Corporation to Participate in the Lake Street Best Ideas Growth Conference
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, announced today that management will participate in the Lake Street Best Ideas Growth Conference, which is being...
Apyx Medical Corporation (APYX) CEO Charles Goodwin on Q2 2022 Results - Earnings Call Transcript
Apyx Medical Corporation (NASDAQ:APYX ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Charles Goodwin – President and Chief Executive Officer Tara Semb – Chief Financial Officer Conference Call Participants Dave Turkaly – JMP Securities...
Source: https://incomestatements.info
Category: Stock Reports